Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia

Podobne zapisy

• Induction of AML Preleukemic Fusion Genes in HSPCs and DNA Damage Response in Preleukemic Fusion Gene Positive Samples
  od: Pavol Kosik, i wsp.
  Wydane: (2021-03-01)
• Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia
  od: Tracy Murphy, i wsp.
  Wydane: (2023-06-01)
• Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia
  od: Robert Puckrin, i wsp.
  Wydane: (2020-01-01)
• Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis
  od: Victoria V. Grunwald, i wsp.
  Wydane: (2019-09-01)
• Genomic profiles and outcomes in de novo versus therapy-related core binding factor AML
  od: May Chiu, i wsp.
  Wydane: (2024-10-01)